Methods: A comprehensive literature search was performed in electronic databases including PubMed, EMBASE and the Cochrane Library (last search March 2012). There were no restrictions to publication time or language. Radical cystectomy with EL was the trial arm (extended lymphadenectomy, EL group), and radical cystectomy with non-EL (standard or local lymph node dissection, non-EL group) was the control arm. The software of RevMan5.1 and Stata11 were used for this meta-analysis (MTA). Data including 5-year overall survival (5-year OS), and 5-year recurrence-free survival (5-year RFS) and total recurrence (TR) were extracted from the EL arm and non-EL arm respectively. Useing the index of hazards ratio (HR), odds ratio (odds ratio, OR) or the weighted mean difference (WMD) to express the result for the categorical variable. Results: Ten studies published from 1998 to 2012 fulfilled the inclusion criteria and were included in the meta-analysis. There was one prospective non-randomized controlled study, and the remaining studies were retrospective. Analysis was performed on 1865 patients in the EL arm and 1,524 in the non-EL arm. The results show that the lymph node numbers (LNs) increased significantly, and there were significant differences (WMD16.79, 95% CI, 11.14-22.43; P<0.00001); lymph node density (LD) were no significant differences (OR 1.39, 95% CI, 0.97-2.01; P=0.07); There were no significant differences in 5-year overall survival (HR 0.84,95% CI, 0.66-1.08; P=0.17); 5-year recurrence-free survival were higher in EL arm (HR 0.81, 95% CI, 0.68-0.98; P=0.03); There were no significant differences in total recurrence (OR 0.89, 95% CI, 0.75-1.05; P=0.17). There was no significant difference in peri-operative complication (P=0.08). Conclusions: This study showed that radical cystectomy with extended lymph node dissection can improve the patient's 5-year recurrence-free survival, but no sufficient evidence can improve the 5-year overall survival and reduce the overall recurrence. Extended lymph node dissection does not increase peri-operative morbidity and mortality. AB046. The evaluation of therapeutic efficiency of relapse prevention of alternating bladder perfusion with GEM and THP after TURBT of superficial bladder cancer
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Objective: To observe the therapeutic efficiency of relapse prevention of alternating bladder perfusion with GEM and THP after TURBT of superficial bladder cancer. Methods: Ninety-two cases of bladder urothelial carcinoma (BUC) patients with TURBT after transurethral catheterization regularly alternating GEM and THP bladder perfusion, total time limit of 19 months after operation, respectively in 3, 6 and 12 months were followed up by cystoscope or CT. After the end of treatment, review again every 6 or 12 months according to the previous review results, for five consecutive years. Results: During the five years, 23 cases of local recurrence, the recurrence rate was 26.4% (23/87), 4 cases of local recurrence and metastasis, recurrence and metastasis rate was 4.6% (4/87), 2 cases of death, mortality was 2.3% (2/87),died of the other disease not related with this one in 9 cases, 5 cases lost follow-up. Conclusions: GEM and THP as the adjuvant chemotherapy drugs after TURBT of superficial bladder cancer, has significant characteristic of curative effect does with small side effects to improve prognosis, decrease recurrence and the mortality rate, may become one of the important means to improve the postoperative curative effect. 
